October 6, 2016
On September 30th, An op-ed appeared in the Detroit News, authored by Marcia Horn, President and CEO of the International Cancer Advocacy Network (ICAN), an ASBM Steering Committee member. Ms. Horn discusses how legislation permitting biosimilar substitution could help Michigan patients. Similar legislation has been passed in 25 states and Puerto Rico. A key provision […]
September 29, 2016
On Friday, September 23rd the FDA approved its fourth biosimilar, Amjevita (adalimumab-atto). Amjevita (adalimumab-atto) was approved for seven adult indications of its reference product, Humira (adalibumab): moderately to severely active rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis (an arthritis that affects the spine); moderately to severely active Crohn’s disease; moderately to severely active ulcerative colitis; and […]
September 28, 2016
SÁO PAULO, BRAZIL- The Latin American Chapter of the Alliance for Safe Biologic Medicines (ASBM) and the Global Colon Cancer Association (GCCA) today participated in a biologics and biosimilars forum in Sáo Paulo, Brazil. The chapter is comprised of eight patient organizations representing a variety of disease groups including multiple forms of cancer, hepatitis, and […]
September 28, 2016
SÁO PAULO, BRAZIL- The Latin American Chapter of the Alliance for Safe Biologic Medicines (ASBM) and the Global Colon Cancer Association (GCCA) today participated in a biologics and biosimilars forum in Sáo Paulo, Brazil. The chapter is comprised of eight patient organizations representing a variety of disease groups including multiple forms of cancer, hepatitis, and […]
September 21, 2016
By Michael Reilly, Executive Director, ASBM To date, the FDA has approved three biosimilars. The first, Zarxio (filgrastim-sndz), used a meaningful, memorable suffix based on the manufacturers name (Sandoz). The second two use the random suffixes “-dyyb” and “-szzs” which mean, well, nothing. ASBM’s surveys have shown that physicians (78%) and pharmacists (85%) support memorable […]
September 21, 2016
By Michael Reilly, Executive Director, ASBM To date, the FDA has approved three biosimilars. The first, Zarxio (filgrastim-sndz), used a meaningful, memorable suffix based on the manufacturers name (Sandoz). The second two use the random suffixes “-dyyb” and “-szzs” which mean, well, nothing. ASBM’s surveys have shown that physicians (78%) and pharmacists (85%) support memorable […]
September 15, 2016
On September 15th, 2016, ASBM held an educational forum at the University of the Sciences in Philadelphia (USciences). The program drew 50 attendees comprised of pharmacists, faculty members, pharmacy students. The program began with an introduction to biosimilars from USciences Associate Professor of Pharmaceutical Sciences Dr. Zhiyu Li. Dr. Li is Director of Undergraduate Pharmacology/Toxicology Program, where he […]
September 15, 2016
A Picture is worth a thousand words… Why Memorable Names are preferred by Pharmacists by Philip Schneider, MS FASHP Associate Dean, University of Arizona College of Pharmacy ASBM Advisory Board Chair Yesterday, I was in Philadelphia with a group of about 50 pharmacy students and faculty speaking about biosimilars and the role they do play and […]
September 15, 2016
A Picture is worth a thousand words… Why Memorable Names are preferred by Pharmacists by Philip Schneider, MS FASHP Associate Dean, University of Arizona College of Pharmacy ASBM Advisory Board Chair Yesterday, I was in Philadelphia with a group of about 50 pharmacy students and faculty speaking about biosimilars and the role they do play and […]
July 25, 2016
On Friday, July 22nd, The Alliance for Safe Biologic Medicines and MedChi, the Maryland State Medical Society co-hosted a forum entitled “Biosimilars: New Choices, New Challenges”. The event was attended by more than 45 physicians, legislators, patient advocates, healthcare workers, and others. MedChi’s CEO, Gene Ransom III began the forum with a discussion of the importance of biosimilars […]
